- ASSISTANT PROFESSOR Pediatrics, Hematology/Oncology
Pediatric Hematology & Oncology
American Board of Pediatrics
- Acute lymphoblastic leukemia (ALL)
- Acute myelogenous leukemia (AML)
- Ewing Sarcoma
- Osteogenic sarcoma
- Pediatric brain tumors
- Post transplant lymphoproliferative disease (PTLD)
- Wilms tumor
MD, Christian-Albrecht Universitat
New York University Medical Center
New York University Medical Center
Dr. Birte Wistinghausen is the Clinical Director of the Division of Pediatric Hematology/Oncology, and Assistant Professor of Hematology/Oncology at The Mount Sinai School of Medicine.
Dr. Wistinghausen earned her medical degree at Christian-Albrecht Universitat Kiel in 1993. After a two-year postdoctoral fellowship in the laboratory of Dr. Margaret Karpatkin describing a novel mutation leading to factor IX deficiency she went on to complete an internship and a residency in Pediatrics at New York University Medical Center in New York. She completed her fellowship in pediatric hematology-oncology at New York University Medical Center and Bellevue Hospital and received her first faculty appointment at New York University Medical Center.
As Clinical Director of Pediatric Hematology and Oncology, Dr. Wistinghausen specializes in diagnosing and treating pediatric patients with leukemia, lymphoma, Langerhans cell histiocytosis and pediatric solid tumors as well as treating selected benign hematological problems of childhood such as ITP, hemophagocytic lymphohistiocytosis (HLH) and hematological complications of solid organ transplantation. Dr. Wistinghausen’s research interests focus on clinical and translational research in non-Hodgkin lymphoma and post-transplant lymphoproliferative disease (PTLD). She currently serves as the institutional principal investigator for the Children’s Oncology Group and is a member of the NHL committee of the Children’s Oncology Committee where she has been appointed to spearhead the clinical research for B-lymphoblastic lymphoma in childhood and to develop a new national clinical and translational research protocol for the treatment of post-transplant lymphoproliferative disease with cellular based therapies. Dr. Wistinghausen has published articles about factor XI deficiency, hematological complications of solid organ transplantation, HLH and PTLD.
First Sydney Q. Cohlan Resident and Fellow Research Award
Department of Pediatrics, New York University Medical Center
Wistinghausen B, Reischer A, Oddoux C, Ostrer H, Nardi M, Karpatkin M. Severe factor XI deficiency in an Arab family associated with a novel mutation in exon 11. Br J Haematol 1997 Dec; 99(3): 575-7.
Lee CK, Raz R, Gimeno R, Gertner R, Wistinghausen B, Takeshita K, De Pinho RA, Levy DE. STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation. Immunity 2002 Jul; 17(1): 63-72.
- AAML1031: A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND#69896, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD
- A Phase III Randomized Trial of Adding Vincristine-topotecan- cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma
- ARST0332: Risk-Based Treatment for Pediatric Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS)
- AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND#73789, NSC# 606869) in the Very High Risk Stratum
- ARST0531 - Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC alternating with Vincristine and Irinotecan Hydrochloride in Combination With Radiotherapy for Patients with Intermediate Risk Rhabdomyosarcoma( RMS)
- Phase III Randomized Study of Chimeric Anti-GC2 in high risk neuroblastoma following myeloablative therapy and autologous stem cell rescue (Protocol - ANBL0032) (Brain)
- Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
- AALL0932: Treatment of Patients with Newly Diagnosed Standard Risk B-precursor Acute Lymphoblastic Leukemia (ALL)
- Intensified Methotrexate,Nelarabine & Augmented BFM Ther (AALL0434)
- Vincritine, Dactinomycin and Cyclophosphomaide for Rhabdomyosarcoma (Sarcoma)
- AREN0534: Treatment for Patients with Bilateral, Multicentric, or Bilaterally- Predisposed Unilateral Wilms Tumor
- ANHL1131: Intergroup Trial for Children or Adolescents with B-cell Non-Hodgkin Lymphoma NHL or Mature B-cell Leukemia B- AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Wistinghausen did not report having any of the following types of financial relationships with industry during 2012 and/or 2013: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
1468 Madison Avenue, 4th Floor
New York, NY 10029
- Monday 9:00am - 5:00pm
- Tuesday 9:00am - 5:00pm
- Wednesday 9:00am - 5:00pm
- Thursday 9:00am - 5:00pm
- Friday 9:00am - 5:00pm
- 1199 National Benefit Fund
- Aetna U.S. Healthcare
- Aetna U.S. Healthcare - HMO
- Blue Choice
- Blue Choice - HMO
- Blue Cross/ Blue Shield
- Blue Cross/ Blue Shield - HMO
- CIGNA Healthcare HMO
- CarePlus, LLC
- CenterCare, Inc.
- Empire Blue Cross/ Blue Shield - HMO
- Empire Blue Cross/Blue Shield
- Empire Health Choice, Inc.
- Fidelis Care NY
- Fidelis Care NY - HMO
- GHI HMO Select, Inc.
- Group Health Insurance, Inc.
- HIP Medicaid
- Health Insurance Plan (HIP)
- HealthPlus, Inc.
- Horizon Healthcare
- Horizon Healthcare - HMO
- Neighborhood Health Providers, LLC
- Oxford Health Plans
- United Health Care Empire Plan
- United Health Care Empire Plan - HMO
- United Healthcare
- United Healthcare - HMO
- Vytra - HMO
- Master Card
- American Express
- Personal Check